Skip to content
Search

Latest Stories

Submit Guest Post

Cairn Energy ends billion-dollar tax dispute with India

Cairn Energy ends billion-dollar tax dispute with India

SCOTTISH oil and gas producer Cairn Energy will drop legal claims against India in return for a $1 billion government refund after lawmakers ditched a tax rule allowing massive retroactive claims.

New Delhi introduced a law in 2012 that gave authorities power to claim back taxes from enterprises that acquired the assets of Indian companies.


Cairn had successfully challenged the claims through international arbitration tribunals, but India refused to accept the rulings.

Legislators scrapped the law in August, but the revenue secretary said then that India would still not recognise the tribunal decisions.

Cairn said in a Wednesday statement that its decision would allow for the refund of Rs 79 billion ($1.06bn) collected from the firm.

It had "entered into undertakings with the government" and said it will withdraw, terminate or discontinue its legal challenges to the previous law.

"Cairn is working collaboratively with the government of India towards expediting the refund," the company said.

A special dividend was expected to be paid to shareholders by early 2022, it added.

The company moved earlier this year to seize properties in Paris and Manhattan owned by India to get back the $1.2bn that the tribunal ruled was owed by the government.

There was no immediate comment from New Delhi on the announcement.

(AFP)

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less